(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 16.89% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 37.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Alpha Teknova's revenue in 2026 is $39,801,000.On average, 8 Wall Street analysts forecast TKNO's revenue for 2026 to be $2,408,438,126, with the lowest TKNO revenue forecast at $2,284,089,855, and the highest TKNO revenue forecast at $2,515,228,828. On average, 6 Wall Street analysts forecast TKNO's revenue for 2027 to be $2,764,246,545, with the lowest TKNO revenue forecast at $2,628,175,385, and the highest TKNO revenue forecast at $2,899,996,531.
In 2028, TKNO is forecast to generate $3,521,416,712 in revenue, with the lowest revenue forecast at $3,383,311,443 and the highest revenue forecast at $3,624,995,663.